Menten AI
Leverages synthetic biology, machine learning and quantum computing to create new proteins not found in nature for diverse applications in the pharmaceutical and chemical industries.
Related Content
Menten AI is at the forefront of biotechnology, specializing in the design and optimization of protein-based drugs and enzymes. Leveraging advanced machine learning and quantum computing, the company addresses high unmet medical needs by exploring new chemical spaces and overcoming the limitations of traditional computational methods. Menten AI serves pharmaceutical companies and research institutions, operating in the biotech and healthcare markets. The business model revolves around developing proprietary algorithms and drug candidates, which are then licensed or sold to industry partners. Revenue is generated through licensing fees, milestone payments, and royalties on sales of successfully developed drugs.
Keywords: protein-based drugs, machine learning, quantum computing, biotechnology, peptide macrocycles, protein therapeutics, drug design, healthcare, pharmaceutical, computational biology.